Contrasting LexaGene (OTCMKTS:LXXGF) and Rockwell Medical (NASDAQ:RMTI)

Rockwell Medical (NASDAQ:RMTI) and LexaGene (OTCMKTS:LXXGF) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Analyst Ratings

This is a summary of current ratings and price targets for Rockwell Medical and LexaGene, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rockwell Medical	1	0	1	0	2.00
LexaGene	0	0	0	0	0.00

Rockwell Medical currently has a consensus target price of $20.00, indicating a potential upside of 192.83%. Given Rockwell Medical’s stronger consensus rating and higher probable upside, research analysts plainly believe Rockwell Medical is more favorable than LexaGene.

Valuation & Earnings

This table compares Rockwell Medical and LexaGene”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rockwell Medical	$67.68 million	0.40	-$5.31 million	($1.50)	-4.55
LexaGene	N/A	N/A	N/A	N/A	N/A

LexaGene has lower revenue, but higher earnings than Rockwell Medical.

Profitability

This table compares Rockwell Medical and LexaGene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rockwell Medical	-7.98%	-15.41%	-9.62%
LexaGene	N/A	N/A	N/A

Institutional & Insider Ownership

23.3% of Rockwell Medical shares are held by institutional investors. 4.6% of Rockwell Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Rockwell Medical beats LexaGene on 6 of the 9 factors compared between the two stocks.

About Rockwell Medical

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

About LexaGene

LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts.